Literature DB >> 23540350

Naltrexone and nalmefene: any meaningful difference?

Robert M Swift1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23540350     DOI： 10.1016/j.biopsych.2013.03.002

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  12 in total

1.  Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.

Authors:  Pablo Barrio; Lluisa Ortega; Josep Guardia; Carlos Roncero; Lara Yuguero; Antoni Gual
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

Review 2.  Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders.

Authors:  Tae Woo Park; Peter D Friedmann
Journal:  R I Med J (2013)       Date:  2014-10-01

Review 3.  Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence.

Authors:  Julia M A Sinclair; Sophia E Chambers; Celia J Shiles; David S Baldwin
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

Review 4.  Neurochemical Evidence of Preclinical and Clinical Reports on Target-Based Therapy in Alcohol Used Disorder.

Authors:  Santosh Kumar Prajapati; Shubham Bhaseen; Sairam Krishnamurthy; Alakh N Sahu
Journal:  Neurochem Res       Date:  2020-01-02       Impact factor: 3.996

5.  Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder.

Authors:  Damian Karl; J Malte Bumb; Patrick Bach; Christina Dinter; Anne Koopmann; Derik Hermann; Karl Mann; Falk Kiefer; Sabine Vollstädt-Klein
Journal:  Psychopharmacology (Berl)       Date:  2021-04-12       Impact factor: 4.530

Review 6.  Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials.

Authors:  Clément Palpacuer; Bruno Laviolle; Rémy Boussageon; Jean Michel Reymann; Eric Bellissant; Florian Naudet
Journal:  PLoS Med       Date:  2015-12-22       Impact factor: 11.069

7.  Morphine promotes cancer stem cell properties, contributing to chemoresistance in breast cancer.

Authors:  Dong-Ge Niu; Fei Peng; Wei Zhang; Zhong Guan; Hai-Dong Zhao; Jing-Lin Li; Kai-Li Wang; Ting-Ting Li; Yan Zhang; Fei-Meng Zheng; Fan Xu; Qian-Ni Han; Peng Gao; Qing-Ping Wen; Quentin Liu
Journal:  Oncotarget       Date:  2015-02-28

8.  Evaluation in alcohol use disorders - insights from the nalmefene experience.

Authors:  Florian Naudet; Clément Palpacuer; Rémy Boussageon; Bruno Laviolle
Journal:  BMC Med       Date:  2016-08-18       Impact factor: 8.775

Review 9.  The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.

Authors:  Jarred Younger; Luke Parkitny; David McLain
Journal:  Clin Rheumatol       Date:  2014-02-15       Impact factor: 2.980

Review 10.  Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers.

Authors:  Niamh Fitzgerald; Kathryn Angus; Andrew Elders; Marisa de Andrade; Duncan Raistrick; Nick Heather; Jim McCambridge
Journal:  Addiction       Date:  2016-06-05       Impact factor: 6.526
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.